FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions refers to a pharmaceutical combination with anxiolytic action. Combination with anxiolytic action for treating neurotic and psychic disorders involves phenazepam, vitamin B6 and magnesium and represents a set of dosage forms containing phenazepam, vitamin B6 and magnesium in effective amounts, or represents a single dosage form, wherein the dosage form containing phenazepam contains 0.1–10 mg of phenazepam, the dosage form containing vitamin B6 contains 0.1–600 mg of vitamin B6, the dosage form containing magnesium contains 10–1200 mg of magnesium. Set of dosage forms and a method of treating neurotic and psychic disorders are also disclosed.
EFFECT: group of inventions provides a synergistic enhancement of anxiolytic effect of phenazepam combined with magnesium and vitamin B6 with simultaneous reduction of side effects of phenazepam.
23 cl, 5 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION IN ORAL DISPERSIBLE FORM WITH THERAPEUTIC ACTION ON ACTIVATING AND INHIBITORY FUNCTIONS OF NERVOUS SYSTEM (VERSIONS) | 2011 |
|
RU2464013C1 |
| PERORAL MEDICAL PRODUCT FOR OFFSET OF MAGNESIUM DEFICIENCY IN ORGANISM | 2006 |
|
RU2336076C2 |
| PHARMACEUTICAL COMPOSITION POSSESSING SEDATIVE AND ANXYOLITIC ACTION | 2008 |
|
RU2361599C1 |
| BIOLOGIALLY ACTIVE AGENT HAVING EFFECT ON GENERAL METABOLIC, EXCITATORY AND INHIBITORY NERVE FUNCTION AND INTELLECTUAL MNESTIC CEREBRAL FUNCTIONS (VERSIONS) | 2011 |
|
RU2461374C1 |
| PHARMACEUTICAL COMPOSITION COMPRISING COMBINATION OF GLYCINE AND TETRAMETHYLTETRAAZABICYCLOOCTANDIONE (VERSION) | 2015 |
|
RU2576240C1 |
| SOLUTION FOR INTRAVENOUS AND INTRAMUSCULAR INTRODUCTION BASED ON BROMO-DIHYDROCHLOR-PHENYL-BENZODIAZEPINE AND METHOD OF PREPARATION THEREOF | 2015 |
|
RU2605824C1 |
| ANTICONVULSANT AND TRANQUILISING AGENT | 2015 |
|
RU2593885C1 |
| PHARMACEUTICAL COMPOSITION SHOWING SOPORIFIC, SEDATIVE AND TRANQUILIZING ACTIVITY, METHOD OF ITS PREPARING | 2001 |
|
RU2183121C1 |
| PHARMACEUTICAL COMPOSITION FOR THE ELIMINATION OF CONVULSIVE SYNDROME BASED ON NIKETHAMIDE AND MEDICINAL PRODUCTS OF THE BENZODIAZEPINE GROUP | 2022 |
|
RU2801050C1 |
| PHARMACEUTICAL AGENT FOR ARTHRITIC DISEASES TREATMENT | 2020 |
|
RU2739746C1 |
